Calculation of sample size in survival trials: The impact of informative noncompliance

Biometrics

Volumn 60, Issue 3, 2004, Pages 800-806

  Jiang, Qi ^a   Snapinn, Steven ^b   Iglewicz, Boris ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b AMGEN INC   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Censored observations; Discontinuation; Exponential distribution; Modified Lakatos method; Survival analysis

Indexed keywords

CENSORED OBSERVATIONS; CLINICAL TRIAL; DISCONTINUATION; EXPONENTIAL DISTRIBUTIONS; HIGH RATE; LAKATOS; MODIFIED LAKATOS METHOD; SAMPLE SIZES; SIZE CALCULATIONS; SURVIVAL ANALYSIS;

RISK PERCEPTION;

SAMPLING; SURVIVAL;

CALCULATION; DATA BASE; HUMAN; OUTCOMES RESEARCH; PATIENT COMPLIANCE; REVIEW; SAMPLE SIZE; SURVIVAL; TREATMENT WITHDRAWAL;

EID: 4444368600     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0006-341X.2004.00231.x     Document Type: Review

References (12)

1. Carnahan, B., Luther, H. A., and Wilkes, J. O. (1969). Numerical integration. Applied Numerical Methods. New York: John Wiley.
2. Halperin, M., Rogot, E., Gurian, J., and Ederer, F. (1968). Sample sizes for medical trials with special reference to long-term therapy. Journal of Chronic Disease 21, 13-24.
3. Jiang, Q., Snapinn, S. M., and Iglewicz, B. (2003). Sample size calculation for survival data. In The Encyclopedia of Biopharmaceutical Statistics, 2nd edition, 892-898. New York: Marcel Dekker.
4. Lachin, J. M. and Foulkes, M. A. (1986). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42, 507-519.
5. Lakatos, E. (1986). Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Controlled Clinical Trials 7, 189-199.
6. Lakatos, E. (1988). Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44, 229-241.
7. Newby, L. K., Hasselblad, V., Armstrong, P. W., Van de Werf, F., Mark, D. B., White, H. D., Topol, E. J., and Califf, R. M. (2003). Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. European Heart Journal 24, 182-189.
8. Schork, M. A. and Remington, R. D. (1967). The determination of sample size in treatment-control comparisons for chronic disease studies in which drop-out or non-adherence is a problem. Journal of Chronic Disease 20, 233-239.
9. Snapinn, S. M., Jiang, Q., and Iglewicz, B. (2004). Informative noncompliance in endpoint trials. Current Controlled Trials in Cardiovascular Medicine 5:5.
10. The SOLVD Investigators. (1990). Studies of left ventricular dysfunction (SOLVD) - rationale, design and methods: Two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. The American Journal of Cardiology 66, 315-322.
11. The SOLVD Investigators. (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The New England Journal of Medicine 327, 685-691.
12. Wu, M., Fisher, M., and DeMets, D. (1980). Sample sizes for long-term medical trial with time-dependent dropout and event rates. Controlled Clinical Trials 1, 109-121.